ОСОБЕННОСТИ МЕДИКАМЕНТОЗНОЙ ТЕРАПИИ АНЕМИИ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК
Keywords:
анемия, хроническая болезнь почек, стимуляторы эритропоэза, железо, гепсидин.
Abstract
Анемия является частым осложнением хронической болезни почек (ХБП) и связана со снижением качества жизни, повышенной заболеваемостью и смертностью. Механизмы развития анемии, связанной с ХБП, разнообразны и сложны. Они включают, среди прочего, снижение продукции эндогенного эритропоэтина (ЭПО), абсолютный или функциональный дефицит железа и воспаление с повышенным уровнем гепсидина. Пациентам чаще всего назначают пероральные или внутривенные препараты железа и препараты, стимулирующие эритропоэз (ЭПО). Однако, эти методы лечения сопряжены с риском и иногда недостаточно эффективны. Тем не менее, в последние годы были достигнуты значительные успехи в лечении анемии, связанной с ХБП, которые породили большие надежды. В данной статье рассматриваются современные знания о патофизиологии анемии, связанной с ХБП, современных и будущих методах лечения, тенденциях в ведении пациентов с неудовлетворенными целевыми уровнями.
References
1. Дедов И.И., Мельниченко Г.А., М. Алгоритмы оказания специализированной медицинской помощи больным сахарным диабетом, издание 4 дополненное, изд.: ООО «Информполиграф», 2019. – 104 с.
2. Дедов И.И., М.В. Шестакова. Сахарный диабет: руководство для врачей М., Universum Publishing, 2013. – 455 с.
3. IDF Диабет Атлас 2021 – 10-е издание.
4. Фируза Тахирова, Нодира Алиханова; Сахарный диабет в Ташкентской области Узбекистана/Endocrine Abstracts (2022) 81 EP1189.
5. Sh, Djuraeva A., and B. K. Badridinova. "METHODS FOR PREVENTING THE DEVELOPMENT OF TERMINAL RENAL FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS." British Medical Journal 2.1 (2022).
6. Kamalidinovna, B. B. (2022). Features of Phosphoric-Calcium Exchange in Patients Treated with Program Hemodialysis. Research Journal of Trauma and Disability Studies, 1(2), 39–45. Retrieved from http://journals.academiczone.net/index.php/rjtds/article/view/60
7. Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L DNL. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant. (2012) 27:2880–6. 10.1093/ndt/gfs007
8. Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, et al. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta- analysis in a global consortium. Am J Kidney Dis. (2019) 73:206–17. 10.1053/j.ajkd.2018.08.013
9. Portolés J, Gorriz JL, Rubio E, De Alvaro F, García F, Alvarez-Chivas V, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. (2013) 14:2. 10.1186/1471-2369-14-2
10. Evans M, Bower H, Cockburn E, Jacobson SH, Barany P, Carrero J-J. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J. (2020) 13:821–7. 10.1093/ckj/sfaa054
11. AG, Alghali A, Li X, Ferguson JP, Casserly LF, Cronin CJ, et al.. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. Clin Kidney J. (2018) 11:99–107. 10.1093/ckj/sfx060
12. KDIGO Anemia Working Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. (2012) 2:279–335. 10.1038/kisup.2012.38
13. Marsch E, Demandt JA, Theelen TL, Tullemans BM, Wouters K, Boon MR, et al.. Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. Eur Heart J. (2016) 37:2993–7
14. Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, et al.. Inflammation and progression of CKD: the CRIC study. Clin J Am Soc Nephrol. (2016) 11:1546–56. 10.2215/CJN.13121215
15. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, Von Haehling S, Doehner W, et al.. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. (2016) 18:786–95. 10.1002/ejhf.473
16. Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC. An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney Int. (2019) 96:750–60. 10.1016/j.kint.2019.04.029
17. Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant. (2021) 36:129–36. 10.1093/ndt/gfz192
18. van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol. (2020) 16:77–98. 10.1038/s41581-019-0197-5
19. Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol. (2020) 31:456–68. 10.1681/ASN.2019020213
20. Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, et al.. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the chronic kidney disease outcomes and practice patterns study: often unmeasured, variably treated. Clin Kidney J. (2019) 13:613–24. 10.1093/ckj/sfz091
21. Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, et al.. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci Rep. (2021) 11:1784. 10.1038/s41598-020-79254-6
22. Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. (2019) 30:1037–48. 10.1681/ASN.2018101007
23. Locatelli F, Hannedouche T, Fishbane S, Zoe Morgan DO, White WB. Cardiovascular safety and all-cause mortality of methoxy polyethylene glycol-epoetin beta and other erythropoiesis-stimulating agents in anemia of CKD a randomized noninferiority trial. CJASN. (2019) 14:1701–10. 10.2215/CJN.01380219
24. Jhund PS, Petrie MC, Robertson M, et al., on behalf of the PIVOTAL Investigators and Committees. Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. JACC Heart Fail 2021;9:518-27.
2. Дедов И.И., М.В. Шестакова. Сахарный диабет: руководство для врачей М., Universum Publishing, 2013. – 455 с.
3. IDF Диабет Атлас 2021 – 10-е издание.
4. Фируза Тахирова, Нодира Алиханова; Сахарный диабет в Ташкентской области Узбекистана/Endocrine Abstracts (2022) 81 EP1189.
5. Sh, Djuraeva A., and B. K. Badridinova. "METHODS FOR PREVENTING THE DEVELOPMENT OF TERMINAL RENAL FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS." British Medical Journal 2.1 (2022).
6. Kamalidinovna, B. B. (2022). Features of Phosphoric-Calcium Exchange in Patients Treated with Program Hemodialysis. Research Journal of Trauma and Disability Studies, 1(2), 39–45. Retrieved from http://journals.academiczone.net/index.php/rjtds/article/view/60
7. Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L DNL. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant. (2012) 27:2880–6. 10.1093/ndt/gfs007
8. Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, et al. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta- analysis in a global consortium. Am J Kidney Dis. (2019) 73:206–17. 10.1053/j.ajkd.2018.08.013
9. Portolés J, Gorriz JL, Rubio E, De Alvaro F, García F, Alvarez-Chivas V, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. (2013) 14:2. 10.1186/1471-2369-14-2
10. Evans M, Bower H, Cockburn E, Jacobson SH, Barany P, Carrero J-J. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J. (2020) 13:821–7. 10.1093/ckj/sfaa054
11. AG, Alghali A, Li X, Ferguson JP, Casserly LF, Cronin CJ, et al.. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. Clin Kidney J. (2018) 11:99–107. 10.1093/ckj/sfx060
12. KDIGO Anemia Working Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. (2012) 2:279–335. 10.1038/kisup.2012.38
13. Marsch E, Demandt JA, Theelen TL, Tullemans BM, Wouters K, Boon MR, et al.. Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. Eur Heart J. (2016) 37:2993–7
14. Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, et al.. Inflammation and progression of CKD: the CRIC study. Clin J Am Soc Nephrol. (2016) 11:1546–56. 10.2215/CJN.13121215
15. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, Von Haehling S, Doehner W, et al.. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. (2016) 18:786–95. 10.1002/ejhf.473
16. Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC. An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney Int. (2019) 96:750–60. 10.1016/j.kint.2019.04.029
17. Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant. (2021) 36:129–36. 10.1093/ndt/gfz192
18. van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol. (2020) 16:77–98. 10.1038/s41581-019-0197-5
19. Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol. (2020) 31:456–68. 10.1681/ASN.2019020213
20. Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, et al.. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the chronic kidney disease outcomes and practice patterns study: often unmeasured, variably treated. Clin Kidney J. (2019) 13:613–24. 10.1093/ckj/sfz091
21. Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, et al.. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci Rep. (2021) 11:1784. 10.1038/s41598-020-79254-6
22. Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. (2019) 30:1037–48. 10.1681/ASN.2018101007
23. Locatelli F, Hannedouche T, Fishbane S, Zoe Morgan DO, White WB. Cardiovascular safety and all-cause mortality of methoxy polyethylene glycol-epoetin beta and other erythropoiesis-stimulating agents in anemia of CKD a randomized noninferiority trial. CJASN. (2019) 14:1701–10. 10.2215/CJN.01380219
24. Jhund PS, Petrie MC, Robertson M, et al., on behalf of the PIVOTAL Investigators and Committees. Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. JACC Heart Fail 2021;9:518-27.
Published
2023-10-09
How to Cite
Бадридинова Б.К., & Бакаев Э.С. (2023). ОСОБЕННОСТИ МЕДИКАМЕНТОЗНОЙ ТЕРАПИИ АНЕМИИ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. Central Asian Journal of Medical and Natural Science, 4(5), 547-555. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1866
Section
Articles
